Navigation Links
Hutchinson Center and TGen scientists discover potential 'break through' in pancreatic cancer
Date:3/20/2012

PHOENIX, Ariz. -- Scientists at Fred Hutchinson Cancer Research Center and the Translational Genomics Research Institute (TGen) have discovered a literal 'break through' in pancreatic cancer.

A unique biological barrier that pancreatic cancer tumors build around themselves have made them especially resistant to chemotherapy treatments, according to the Hutchinson Center/TGen study published today in the highly-regarded journal Cancer Cell.

Pre-clinical experiments show that a combination of drugs could break down the barrier surrounding these tumors, allowing chemotherapy drugs to freely spread and permeate throughout the cancerous tissue, according to the study.

"Discovering how to break through this barrier is a significant finding that could eventually enable therapeutic compounds to be much more effective in combating this deadly cancer and helping patients," said Dr. Daniel Von Hoff, M.D., TGen's Physician-In-Chief and one of the authors of the study, as well as one of the world's leading authorities on pancreatic cancer.

"The barrier surrounding pancreatic ductal adenocarcinoma has prevented therapeutics from reaching and effectively acting on this cancer," said Dr. Von Hoff, who also is head of TGen's Clinical Translational Research Division.

This research is now being tested for the first time in patients in the U.S. and Europe, including those at Seattle Cancer Care Alliance, the Hutchinson Center's patient treatment arm. These tests have the potential to significantly increase the length of survival in patients with pancreatic cancer, which is notoriously fast-spreading and among the most lethal of all cancers, the study says.

Dr. Sunil Hingorani, M.D., Ph.D., the study's senior author and an associate member of the Hutchinson Center's Clinical Research and Public Health Sciences divisions, developed the study's laboratory model. By combining gemcitabine the current standard chemotherapy used to treat patients' pancreatic ductal adenocarcinomas with an enzyme called PEGPH20, scientists showed that the tumor barrier could be broken down and the drug could more easily reach the cancerous tissue.

"This represents the largest survival increase we've seen in any of the studies done in a preclinical model, and it rivals the very best results reported in humans," Dr. Hingorani said. "Being able to deliver the drugs effectively into the tumor resulted in improved survival as well as the realization that pancreas cancer may be more sensitive to conventional chemotherapy than we previously thought."

Unlike most solid tumors, pancreas tumors use a two-pronged defense to keep small molecules, such as those contained in chemotherapy, from entering: a vastly reduced blood supply and the creation of a strong fibro-inflammatory response. The latter includes the production of fibroblasts, immune cells and endothelial cells that become embedded within a dense and complex extracellular matrix throughout the tumor. One major component of this matrix is a substance called hyaluronan, or hyaluronic acid (HA). HA is a glycosaminoglycan, a complex sugar that occurs naturally in the body and is secreted at extremely high levels by pancreatic cancer cells.

Dr. Hingorani, Dr. Von Hoff and their colleagues discovered that the fibro-inflammatory response creates unusually high interstitial fluid pressures that collapse the tumor's blood vessels. This in turn prevents chemotherapy agents from entering the tumors. The researchers found that HA is the main biological cause of the elevated pressures that leads to blood vessel collapse.

Administering the enzyme/gemcitabine combination degrades HA in the tumor barrier and results in rapid reduction of the interstitial fluid pressure. This in turn opens the blood vessels and permits high concentrations of chemotherapy to reach the tumor.


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research
2. Hutchinson Center and China CDC sign agreement for research and training collaboration
3. Fred Hutchinson Cancer Research Center scientist receives Presidential Early Career Award
4. NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer consortium
5. Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network
6. Shanghai CDC and Hutchinson Center establish Shanghai Breast Health Resource Center
7. Hutchinson Center receives $8.2M to coordinate obesity and cancer consortium
8. Fred Hutchinson Cancer Research Center to co-lead 1 of 5 NCI-funded proteomics research centers
9. Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa
10. Hutchinson Center scientists break through pancreas cancer treatment barrier
11. Diet-to-Go Welcomes 2 Key Philadelphia Fitness Centers as Partners-in-Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: